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Interleukin-1f3 up-regulates the plasminogen activator/plasmin
system in human mesangial cells
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Interleukin-1 up-regulates the plasminogen activator/plasmin system
in human mesangial cells. The plasminogen activators (PA), which are
regulated by their specific inhibitor, PAl-i, convert the zymogen plasmin-
ogen to plasmin, a protease involved in fibrinolysis and extracellular
matrix turnover. Interlcukin ill (IL-i) is a key cytokine released from
infiltrating monocytes/macrophages during the initial stages of glomerular
injury. We investigated the effects of IL-i on the production of tissue-type
plasminogen activator (t-PA), urokinase (u-PA) and PAl-i by glomerular
cells. IL-i significantly increased the synthesis of t-PA by mesangial cells
and glomerular epithelial cells (P < 0.005 for both cell types), while u-PA
production was unaltered. PAl-i in mesangial cell supernatants was
significantly lower when cultured in the presence of IL-i (P < 0.008), and
the synthesis decreased in a time and dose dependent manner. The effects
of IL-i were elimininated by anti-IL-i neutralizing antibodies. The PAl-i
sequestered in the extracellular matrix of mesangial cells was also de-
creased. No significant change in PAl-I synthesis by epithelial cells was
observed with exogenous IL-i. Northern blot analysis paralleled the
protein results, demonstrating an increase in t-PA and a decrease in PAT-i
mRNA of mesangial cells after 6 and 24 hours stimulation with iO U/ml
IL-I. These studies suggest a role for IL-i in regulating localized
proteolysis by mesangial cells during acute inflammation.
The matrix surrounding glomerular cells is a dynamic structure,
the mass of which can be altered in glomerular disorders; for
example, it may be decreased by degradation and remodeling
processes and increased in sclerosis. As in other tissues, the
quantity of matrix present, both mesangial matrix and glomerular
basement membrane, is regulated by matrix synthesis and by
specific enzymatic degradation. The plasminogen activator (PA)!
plasmin system is a general proteolytic system that has been
implicated in matrix degradation in several situations such as
ovulation and migration of tumor and inflammatory cells [1].
There are two types of PA, urokinase (u-PA) and tissue-type
plasminogen activator (t-PA), both of which convert the zymogcn
plasminogen into plasmin. Mesangial cells have been reported to
produce t-PA and PAl-i [2, 3] and in some cases u-PA and PAI-2
[4, 5]. Glomerular epithelial cells produce u-PA, t-PA and PAl-i
[2]. Plasmin degrades the fibrin component of thrombi as well as
certain extracellular (ECM) components such as laminin and
fibronectin, and is important in the resolution of inflammation.
Plasmin can activate latent elastases, collagenases and gelatinases,
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which also degrade ECM [6—8). Furthermore, it is likely that
plasmin modulates the activity and release of specific cytokines
from the ECM, which in turn can influence matrix turnover. The
generation of plasmin is regulated by specific inhibitors of PA,
particularly plasminogen activator inhibitor-i (PAl-i). PAl-i is
localized and stabilized in matrix by binding to ECM components
[9]. Plasminogen activators, their inhibitors and plasmin therefore
play a critical role in maintaining glomerular function, both by
controlling glomerular fibrin deposition and by influencing the
turnover of extraccllular matrix.
Several potent cytokines have been identified within the in-
flamed glomerulus in human tissue and in animal models of
glomerulonephritis. It was of interest to determine how specific
cytokines, known to be up-regulated in glomcrulonephritis, alter
the balance of PA and PAl-i secreted by glomerular cells.
Interleukin 1 (IL-I) is a potent proinflammatory cytokine that is
released in large quantities by activated macrophages [10] in many
inflammatory diseases, including glomerulonephritis. Similarly,
IL-i mRNA is produced by mesangial cells, which are also known
to have receptors for this cytokine [11]. Locally, IL-i mediates
tissue injury and remodeling, by inducing cells to undergo a
co-ordinated response that culminates in the expression of new
structural determinants and functional characteristics. In this
study we examine the effect of IL-i on PA and PAl-i synthesis in
glomerular mesangial cells and epithelial cells, to determine their
possible influence on matrix degradation and remodeling in
glomerular disease.
Methods
Cell cultures
Human glomerular epithelial and mesangial cells were cultured
from the cortex of histologically normal portions of the non-
involved poles of nephrectomy specimens removed because of the
presence of a tumor. Glomeruli were isolated from the renal
cortex by a standard three-stage sieving method as described
previously [12]. In brief, the renal cortex was passed sequentially
through stainless steel sieves of size 250, 150 and 106 m. The
smallest pore size retained the glomeruli, which were transferred
to 80 ml tissue culture flasks. The glomeruli were cultured in
RPMI 1640 medium supplemented with (all final concentrations)
2 mM L-glutamine, 100 lU/mI penicillin, 100 jg/ml streptomycin,
10% fetal calf serum (heat inactivated at 56°C for 45 mm), 5 ji.g/ml
insulin and 5 g/ml transferrin and 30 m selenium growth
supplement (all reagents from Gibco Ltd, Paisley, Scotland). The
glomeruli were incubated at 37°C in a humidified 5% CO2
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incubator. Experiments were performed on whole glomeruli
immediately after isolation. Mesangial cells appeared from the
glomeruli around 8 to 14 days after attachment. They were
allowed to stack after confluency until they outgrew all epithelial
cells present. Cells were used between passes 3 and 5. Epithelial
cells were prepared from glomeruli by selecting isolated groups of
homologous cells, identified by their morphological features. They
were grown in RPM! 1640 medium supplemented as above but
containing only 2.5% fetal calf serum. All experiments on epithe-
hal cells were performed at pass 3.
Cell characterization
Mesangial and epithelial cells were characterized by immuno-
cytochemistry. Labeling of cells was achieved using the alkaline
phosphatase, anti-alkaline phosphatase (APAAP) technique [13].
Mesangial cells stained positively for fibronectin and smooth
muscle cell actin. They were negative for cytokeratin and von
Willebrand factor (an endothelial cell marker). Epithelial cells
were positive for cytokeratin and PHM-5 (an anti-human glomer-
ular epithelial cell antibody) and were negative for smooth muscle
cell actin and von Willebrand factor. Epithelial cells were poly-
hedral in shape at confluency.
Stimulation of cells/glomeruli
The mesangial and epithelial cells were plated onto 24-well
plastic culture plates and grown until confluent. Cells were
washed with 0.15 M NaCI, 10 m phosphate buffer, pH 7.4 (PBS).
Fresh medium with or without IL-i (Boehringer Mannheim, Bell
Lane, Lewes, East Sussex, UK) was then added. Where serum-
free medium was used, 0.5% BSA was included in the medium.
Unless otherwise stated the concentration of IL-i added to cells
was 10 U/ml. In selected experiments, anti-IL-i neutralizing
antibody (R & D systems, Abington, Oxon, UK) or an unrelated,
control IgG (mouse anti-rat T lymphocyte suppressor cell anti-
body), both at 10 j.Lg/ml, was added. Supernatants were removed
separately from triplicate wells at the time points 0, 8, 24, 30, 48
and 72 hours. Cells were detached from wells with 1 mM EDTA in
PBS and the complete removal of cells monitored by microscopy.
Viable cells were counted at each time point after staining with
Acridine Orange. Matrix was recovered by vigorous scraping of
the culture wells in the presence of 0.1% SDSIPBS (wt/vol). This
removed essentially all matrix as assessed by subsequent immu-
nohistochemistry using fibronectin and collagen as matrix protein
markers. Whole glomei-uli were plated onto 6-well plastic plates at
a density of approximately 500 glomeruli per well. Before sam-
pling, glomeruli were sedimented by centrifugation at 1000 rpm
for four minutes. They were then washed in PBS, recentrifuged
and resuspended in 10 ml medium, with or without IL-i.
Detection and quantification of PAl-i, u-PA and t-PA
The PAl-i concentration in the cell culture supernatant was
determined by enzyme-linked immunosorbent assay (EL!SA), as
previously described [14]. The assay is sensitive to 30 pg/mI and
measures all forms of PAl-i to the same extent. The amount of
PAl-i antigen present in the ECM of cells was quantified by the
same ELISA. The matrix samples, collected as described above,
were diluted to a final SDS concentration of 0.05%. SDS was
incorporated in the standard curve at the same concentration to
correct for minor effects on the ELISA.
The u-PA concentration was determined using the Biopool
TintElize u-PA kit, which is sensitive to 100 pg/ml, while the t-PA
concentration was determined by an ELISA, which is sensitive to
50 pg/rn! [15]. Culture supernatant and the culture medium did
not contain any detectable PAl-i, u-PA or t-PA prior to incuba-
tion with cells.
The sensitive technique of zymography was utilised to detect
low concentrations of plasminogen activators (free and complexed
with PAl-i), as previously described [16]. SDS-PAGE was per-
formed under non-reducing conditions on a 10% polyacrylamide
gel. Removal of SDS was achieved by washing in 2.5% Triton
X-100 and PA activity visualized on a fibrin agarose detector gel
containing fibrinogen (2 jg/ml), thrombin, (0.06 U/rn!) plasmin-
ogen (2 j.tg/ml) and agarose (0.8%). Incubation was performed at
37°C in a humid atmosphere for about 16 hours, when clear zones
of lysis were evident as dark areas on the photographs shown.
Commercial human u-PA and t-PA were applied as standards and
neutralization by antibodies to u-PA and t-PA was used to
characterize the PA species present in each sample as described
[16]. To detect PM-i, inhibitor fibrin zymography was used where
the entire detector gel was lysed by u-PA (Leo u-PA, 0.075 Ploug
U/mi, final concentration) except where inhibitor bands were
visualized as an opaque zone, as described [17].
DNA probes
A 1200 bp BamHI fragment of human PAl-i eDNA [18] and a
1500 bp PstI fragment of human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) eDNA (American Tissue Culture Col-
lection) was isolated from low melting point agarose and purified
using a Geneclean kit (Cambridge Biosystems). A 338 bp tem-
plate for the t-PA probe was prepared by PCR of mesangial cell
cDNA using specific primers. Probes were labeled by incorpora-
tion of 32P dCTP using random primers and DNA polymerase as
directed in the Amersham multiprime labeling kit.
R1'JA isolation and nucleic acid hybridization
Confluent flasks of cells were incubated for 6 and 24 hours in
growth medium with or without IL-i prior to RNA extraction.
Cytoplasmic RNA was isolated by differential precipitation as
described [19]. RNA (20 jg as determined by absorbance at 260
nm) was incubated for one hour at 50°C with glyoxyl and dimethyl
sulphoxide, before being separated by electrophoresis on a 1%
agarose gel [19] and transferred to Hybond N+. Prehybridization
and hybridization of blots was carried out at 60°C in 0.5 M sodium
phosphate pH 7.2, containing 1 m EDTA, and 7% SDS.
Autoradiography was performed at —70°C using intensif'ing
screens and autoradiographs scanned by densitometry for quan-
titative determination of PAl-i and t-PA mRNA abundance. All
blots were subsequently stripped by boiling in 0.5% SDS and
reprobed with a labeled cDNA for GAPDH which served as a
reference.
Statistical analysis
Results of antigen measurements are expressed in ng/105 cells
with mean values SEM. Student's t-test and two-way analysis of
variance were used as appropriate to compare results.
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Fig. 1. PA I-i antigen in the conditioned medium of mesangial cells after 72
hours of culture at a range of of concentrations of exogenous IL-i. Data are
presented as the mean SEM from three independent experiments, each
performed in triplicate. *f < 0.05, P < 0.01
Results
Mesangial cells constitutively produce t-PA and PAl-I [2]. IL-I
was found to lower the basal levels of PAl-i in the conditioned
medium of mesangial cells at 72 hours (Fig. 1) as compared to
unstimulated control cells. Results presented in this Figure and
subsequent Figures are means SCM of the combined data from
three individual experiments, each performed in triplicate. It has
been suggested that IL-i can induce proliferation in some cell
types and results are therefore presented in all cases in relation to
cell number. In this study, IL-i was found to increase mesangial
cell proliferation by up to 20%. IL-i also decreased PAl-I
production (P < 0.01) when results are expressed simply as ng
PAl-i/well.
The decrease in PAl-i in response to IL-i was significant over
the range of 10 to 100 U/ml and was most marked at 10 U/mi; this
concentration was used in subsequent experiments on mesangial
cells. The effect of IL-i on PAl-i production was confirmed by
zymography where an inhibitor band was detected and was less
intense when mesangial cells were cultured in the presence of IL-i
(data not shown). Neutralizing antibody to IL-i completely
blocked the suppression of PAl-I production induced by IL-i,
whereas control IgG had no effect; this was the case for all
concentrations of IL-I examined (Table 1).
The time course of PAl-i production was followed and overall
IL-i significantly decreased the synthesis of PAT-i (P < 0.008, as
assessed by ANOVA; Fig. 2). At 72 hours the production of PAl-i
was dramatically decreased to half the control value. The level of
PAl-i mRNA was also decreased when cells were cultured in the
presence of IL-I (Fig. 3). Figure 3 represents results from one
typical experiment. Similar results were obtained on two further
occassions using mesangial cells obtained from different donors.
The size of the PAl-I mRNA is consistent with previous data with
a 2.3 kb mRNA and a more abundant, poly-adenylated 3.2
species. The expression of both the 3.2 and 2.3 kb bands of PAl-i
Table 1. Effect of anti-IL-i antibody on IL-i-induced suppression of
the PAl-i antigen release from mesangial cells
PAT-i produced
ng/105 cells
Control 108 1.9
IL-i 71 1.3u
IL-i plus anti-IL-I antibody 101 1.8
Anti-IL-i antibody 103 1.5
IL-i plus control IgG 69 1.5
Control IgG 109 1.4
Cells were incubated for 72 hours in the presence or absence of IL-i at
10 U/mI with or without anti IL-i antibody or a control IgG both at 10
pg/mI. Data are presented as the mean SEM from three independent
experiments, each performed in triplicate.
aP < 0.01 as compared to control, unstimulated cells
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Fig. 2. PAl-i antigen in conditioned medium of mesangial cells treated
without (solid bars) or with (hatched bars) IL-I (10 U/ml) and harvested at
the time points indicated. Data are presented as the mean SEM from three
independent experiments each performed in triplicate. P < 0.08 as
analyzed by ANOVA.
mRNA decreased significantly on stimulation with IL-i, in con-
trast to mRNA for GAPDH which showed unaltered levels.
Densitometric analysis revealed a decrease in the PAI-i/GAPDH
mRNA ratio from 6.7 in untreated control cells to 3.0 after six
hours treatment with IL-I and to 0.5 after 24 hours for the 3.2 kb
PAl-i mRNA species, and a decrease from 3.2 to 1.2 after six
hours and to 0.07 after 24 hours for the 2.3 kb PAl-i mRNA.
Matrix-associated PAT-i was also quantified because of its
importance for localized protection against PA. IL-i significantly
lowered (P < 0.05, as assessed by ANOVA) the concentration of
matrix-associated PAl-i (Fig. 4). The PAl-i content of the matrix
of mesangial cells did not differ significantly over time (Fig. 4). At
the earliest time point (8 hr) the matrix PAT-i constituted as much
as 20% of the total PAl-i, comprising matrix and supernatant.
The proportion of matrix-associated PAl-i was approximately 7%
of the total at 24 to 48 hours, falling to 3% at 72 hours as the
supernatant PAl-i continued to rise.
A significant decrease in PAl-i production with IL-i (10 U/mI)
was also observed when cells were cultured in the absense of
0 0.5 1 10 50 100
IL-i concentrations, U/mi
48 72
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Fig. 4. PAl-I in the matrix of mesangial cells treated without (solid bars) or
with (hatched bars) IL-] (10 U/mI). Mesangial cells were removed and the
matrix recovered in SDS (0.1%). Data are presented as the mean SEM
from three independent experiments, each performed in triplicate. P <
0.05, as analyzed by ANOVA
serum (Table 2). The basal PAl-i level was higher in cultures in
10% FCS than for cultures without serum; consequently the effect
of IL-i was more easily seen in serum-containing medium
There was a striking increase, some 2.5- to 4-fold, in t-PA
synthesis by mesangial cells cultured in the presence of IL-i (Fig.
5), the increase being highly significant (P < 0.005) over the time
course. Similarly, IL-i increased t-PA production from epithelial
Addition No FCS 10% FCS
—
IL-I
63.4 1.2
54.1 1.3
283.1 28
125 139b
of mRNA and densitometric analysis of the autorads showed an
increase in the t-PA/GAPDH mRNA ratio from 1.2 in untreated
control cells to 2.3 and 3.5 after 6 and 24 hours, respectively. The
amount of t-PA released from whole glomeruli suspensions was
low and no significant difference was observed in the presence or
absence of IL-i (0.27 0.05 ng t-PA (no added IL-i), and 0.41
0.13 ng t-PA (plus IL-I), at 72 hours/500 glomeruli). It should be
noted that the t-PA levels produced are close to the limits of
detection in our sensitive ELISA [15].
IL-I had no detectable effect on PAl-i synthesis by glomerular
epithelial cells. The effects of IL-i on PAl-i and PA at a
concentration of 10 U/mI and at 72 hours are shown in Figure 6.
Similar non-significant diferences were observed over a range of
IL-i concentrations from 0.1 to 100 U/ml. PAT-I antigen levels
were examined in all cases at 0, 8, 24, 30, 48 and 72 hours; for
clarity, only the results at time point 72 hours are illustrated.
Similarly, no effect on PAT-i production by whole glomeruli was
observed at any time point examined, for example at 72 hours 5.9
0.4 ng PAT-i (no added IL-i) and 5.7 0.4 ng PAl-i (plus
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Effect of IL-i on PAl-i mRNA
3.2 kb
2.3 kb
GAPDH
Fig. 3. Northern blot analysis of the RNA
isolated from mesangial cells probed for PAl-i(upper bands, 3.2 and 2.3 kb) and GAPDH
(lower band). From left to right tracks are:
mRNA from cells after 24 hours of culture
without (—) IL-i, mRNA from cells cultured
with (+) IL-i for 6 and 24 hours, respectively.
14 Table 2. Effect of IL-i on PAl-i production in the absence or presence
of 10% fetal calf serum
12
Mesangial cells were incubated for 72 hours with or without IL-i in 0 or
10% serum. Data are presented as the mean SEM from three indepen-
dent experiments, each performed in triplicate.
ap < 0.05, bp < 0.01.
cells (Fig. 6). The increase in t-PA was also reflected at the level IL-i) per 500 glomeruli.
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The amount of u-PA produced and secreted by epithelial cells
increased over time. Culture in the presence of IL-i did not result
in any significant change in u-PA production in any case (Fig. 6).
Similarly, no significant difference was found in the production of
u-PA from glomeruli, for example at 72 hours 6.7 0.8 ng u-PA
(no added IL-i) and 7.2 1 ng u-PA (plus IL-i) per 500
glomeruli. Consistent with previous experiments [20], no u-PA
was detected in mesangial cells under these culture conditions.
Activity of t-PA and u-PA in glomeruli, mesangial cell and
epithelial cell supernatants was visualized by zymography on a
fibrin detector gel, where a number of bands were evident (Fig. 7).
Neutralization by specific antibodies showed that the broad band
at 55 to 65 kD was due to u-PA (leading edge) and t-PA (main
band). The free PA was also identified with reference to standard
u-PA (54 kD) and t-PA (65 kD). Free u-PA and t-PA was
identified in glomeruli and epithelial cell supernatants while no
free activator was identified in mesangial cell supernatants. A
complex of u-PA/PAl-i was identified at 100 kD (glomeruli and
epithelial cell supernatants) while i-PA/PAl-i complex was ob-
served at 110 kD (all tracks). Higher molecular mass material at
the top of the gel was identified as being due to PA complexes
such as t-PA-2 macroglobulin [2, 3]. Overall, IL-I increased PA
activity as assessed by zymography and this largely reflects an
increase in t-PA, consistent with the ELISA data.
Endogenous cyclooxygenase products including PGE2 are
thought to be produced in IL-i treated rat mesangial cells [21] and
can, in turn, regulate the levels of certain products under the
control of IL-i. The effect of the cyclooxygenase inhibitor, indo-
methacin, was examined in the presence of absence of IL-i to
determine whether it can abrogate the effect of IL-i. As shown in
Figure 8, the effect of IL-i in down-regulating PAl-I production
was not influenced by indomethacin at a concentration of 1 or 10
j.g/ml. Indomethacin itself decreased the PAT-i antigen to the
same extent as IL-I but the combined treatment caused no further
decrease.
Discussion
The amount and composition of glomerular extracellular matrix
is determined by the balance of its synthesis and proteolytic
degradation. An understanding of the regulation of matrix-de-
grading proteases is important, since they are involved in normal
regulation and contribute to pathological conditions of the kidney.
This study has shown that IL-i influences the secretion of PA and
PAT-i by glomerular cells and may play a role in matrix degrada-
tion and remodeling during the inflammatory phase of glomeru-
lonephritis. This is in contrast to the effects of TGF-/3 on
PA/PAl-i reported previously [21.
IL-i decreased PAl-i production by mesangial cells, both that
secreted into the culture supernatant and the pool bound to the
extracellular matrix, The decrease in PAI-l production by IL-I
was complemented by an increase in i-PA synthesis. Regulation in
both cases was at the level of mRNA. The effects were most
marked at 10 U/ml IL-i; higher concentrations of IL-i resulted in
a less pronounced effect, possibly due to a down-regulation of IL-i
receptors.
Matrix-bound PAl-i is considered to have important local
effects, since its stability is increased in this situation by its binding
to vitronectin [22]. A decrease in matrix-bound PAl-I by IL-i
could lead to an increase in proteolysis, accentuating matrix
degradation and remodeling during inflammation. Matrix-bound
PAl-i binds to and inhibits t-PA, after which t-PA/PAI-1 complex
is released into the supernatant [23]. Thus, the decrease in
matrix-associated PAl-i may also be due to its removal by the
increase in t-PA production by IL-i.
The question arises as to whether endogenous IL-i might have
an effect on PAl-i production. Mesangial cells are known to
produce mRNA for IL-let and 13 and stimulation with IL-1/3
results in a small increase in IL-ia [24]. The amount of IL-i
produced (< 50 pg) by mesangial cells is, however, below the
concentration shown in this study to influence PA/PAl-i. An
increase in glomerular IL-i has been detected in the early stages
of nephritis in several animal models [25] and infiltrating mono-
cytes are most likely to contribute to the levels of IL-i that would
produce a change in PAl-i/PA in vivo.
Like mesangial cells, glomerular epithelial cells increased their
basal production of t-PA when cultured in the presence of IL-i.
This is in agreement with previous data on epithelial cells [26].
The production of PAl-i by epithelial cells was not significantly
altered with exogenous IL-i, in contrast to an earlier study [26],
where an increase (P < 0.05) in PAl-i production with IL-i was
reported. This discrepancy may be explained by the different
culture conditions employed [261. Furthermore, we used TL-1p for
stimulation in all cases where the previous study appear to have
used a combination of IL-ia and 13.
IL-i is generally viewed as a stimulator of PAT-i synthesis in a
variety of cell types [27]. Interestingly, we have demonstrated that
it lowers mesangial cell PAT-i mRNA and protein levels. This
response parallels that found in human synovial fibroblasts [28],
human articular cartilage and chondrocytes [29], and emphasizes
the ability of individual cell types to respond differently to
mediators according to the physiology of the cell type. The
simplest explanation for the decrease in PAl-i by IL-i is a direct
inhibition of PAT-I gene transcription. IL-I stimulates POE2
synthesis by rat mesangial cells, which may inhibit PAT-I synthesis
through cAMP generation [21]. We have shown here, however,
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Fig. 5. t-PA antigen in conditioned medium of mesangial cells treated
without (solid bars) or with (hatched bars) IL-I (10 U/mI). Data are
presented as the mean SEM from three independent experiments, each
performed in triplicate. P < 0.005, as analyzed by ANOVA.
0 8 24 30 48 72
Time, hours
t Cl?L
6200 4
100
that the presence of an inhibitory transcriptional factor that is
positively regulated by IL-i is present in mesangial cells. We are
currently investigating other transcriptional and translational in-
PAl-i production by mesangial cells and when added in combi- hibitors of PAl-i.
nation with IL-i, no further effect was observed, suggesting that IL-i is also known to regulate other proteases. The co-depen-
their mechanism of action may have elements in common. In view dence of matrix destruction on metalloproteinases and serine
of the fact that IL-i generally elevates PAl-i, it may be postulated protease activities has been demonstrated for several model
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Fig. 6. PAl-i, u-PA and t-PA antigen in
conditioned medium of epithelial cells treated
without (solid bars) or with (hatched bars) IL-i
(10 U/mI) for 72 hours. Data are presented as
the mean SEM from three independent
experiments each performed in triplicate. *P <
0.01.
Fig. 7. Fibrin-plasminogen zymogram showing
plasminogen activators secreted from glomeruli or
isolated cells treated without (—) or with IL-i
(+). Supernatants were removed after 72 hours
and subjected to SDS-PAGE and zymography
as described in the methods. Supernatants are
from (a) glomeruli, (b) mesangial cells and (c)
epithelial cells
+ — +
A
+
B C
that the inhibitory effect of PAl-i secretion by IL-i is not blocked
by indomethacin, an inhibitor of PGE synthesis, suggesting a more
complex control of the PAl-i gene. Indomethacin also decreased
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Fig. 8. Cyclooxygenase inhibition and PA!-? regulation. Mesangial cells
were cultured without (solid bars) or with (hatched bars) IL-i for 72 hours
in the absence (control) or presence (1 jig/mI and 10 jig/mI) of the
cycloxygenase inhibitor, indomethacin and PAT-i antigen in the condi-
tioned supernatants assayed by ELISA. Data arc presented as the mean
SEM from three independent experiments each performed in triplicate.
IL-i and indomethacin individually decreased PAT-I in the conditioned
medium (P c 11.05) but there was no dilference in PAT-I levels when cells
were cultured with or without TL- 1 in the presence of indomethaein.
systems including mesangial cells, the two classes of proteases
being linked in an activation cascade [Sj. IL-i has been shown to
increase the production of eollagenases from mesangial cells [30].
Since eollagenases need to be cleaved by plasmin to reveal their
active form, the increase in t-PA production and decrease in
PAl-i (with consequently increased plasmin generation) by IL-I
would complement such a process. TL-l appears, therefore, to
up-regulate net protease activity by mesangial cells.
IL-I is believed to share many properties with tumor necrosis
factor (TNF). Indeed it is known that TNF induces the synthesis
of IL-i. TNF is regarded as anti-fibrinolytie with regard to the
mesangial cell [311, resulting in an increase in PAl-i with no effect
on t-PA production. This is in marked contrast to IL-i, which has
been shown here to be profibrinolytic. Thus, in mesangial cells,
TNF and IL-I appear to have distinct regulatory effects with
regard to PA/PAl-i.
In conclusion, IL-I has been demonstrated to modulate PA and
PAl-i production by glomerular cells. IL-l synthesis is up-
regulated in inflamed glomeruli and this may he important in
regulating matrix degradation and subsequent remodeling during
the inflammatory phase of glomerulonephritis.
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